Literature DB >> 11919229

Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.

Carmen J Allegra1, Allyson L Parr, Lester E Wold, Michelle R Mahoney, Daniel J Sargent, Patrick Johnston, Pam Klein, Katie Behan, Michael J O'Connell, Ralph Levitt, John W Kugler, Maria Tria Tirona, Richard M Goldberg.   

Abstract

PURPOSE: To evaluate the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic markers in patients with Dukes' B2 and C colon carcinoma.
METHODS: We conducted a retrospective analysis to evaluate the prognostic value of TS, Ki-67, and p53 in 465 patients with Dukes' B2 (220 patients) or Dukes' C (245 patients) colon carcinoma. Patients represent a nonrandom subset obtained from five randomized phase III trials and were treated with either surgery alone (151 patients) or surgery plus fluorouracil-based chemotherapy (314 patients). All three markers were assayed using immunohistochemical techniques.
RESULTS: With a minimum follow-up of 5 years, our retrospective analysis failed to demonstrate a consistent and significant association between TS, Ki-67, or p53 and either disease-free survival or overall survival. Exploratory analyses did not reveal a convincing explanation for these results that are in conflict with the published literature. Notable interactions were observed. In particular, high Ki-67 levels were associated with increased (decreased) survival in patients with low (high) TS intensity. Patients whose tumors stained positively for p53 seemed to benefit substantially from the use of adjuvant chemotherapy compared with those who were not treated (P =.05).
CONCLUSION: This retrospective investigation failed to demonstrate a significant association between TS, Ki-67, or p53 staining and clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11919229     DOI: 10.1200/JCO.2002.07.080

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  37 in total

1.  Prognostic impact of bim, puma, and noxa expression in human colon carcinomas.

Authors:  Frank A Sinicrope; Rafaela L Rego; Kenji Okumura; Nathan R Foster; Michael J O'Connell; Daniel J Sargent; Harold E Windschitl
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

2.  Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers.

Authors:  Frank A Sinicrope; Rafaela L Rego; Nathan R Foster; Stephen N Thibodeau; Steven R Alberts; Harold E Windschitl; Daniel J Sargent
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

3.  Bax expression is a candidate prognostic and predictive marker of colorectal cancer.

Authors:  Venkat R Katkoori; Catalina Suarez-Cuervo; Chandrakumar Shanmugam; Nirag C Jhala; Tom Callens; Ludwine Messiaen; James Posey; Harvey L Bumpers; Sreelatha Meleth; William E Grizzle; Upender Manne
Journal:  J Gastrointest Oncol       Date:  2010-12

4.  Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Authors:  David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2019-08-30       Impact factor: 7.842

5.  Differences in telomerase activity between colon and rectal cancer.

Authors:  Georgios D Ayiomamitis; George Notas; Apostolos Zaravinos; Adamantia Zizi-Sermpetzoglou; Maria Georgiadou; Ourania Sfakianaki; Elias Kouroumallis
Journal:  Can J Surg       Date:  2014-06       Impact factor: 2.089

6.  Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.

Authors:  Annelies Debucquoy; Laurence Goethals; Louis Libbrecht; Christiaan Perneel; Karel Geboes; Nadine Ectors; William H McBride; Karin Haustermans
Journal:  Int J Colorectal Dis       Date:  2008-12-03       Impact factor: 2.571

7.  Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.

Authors:  R L Rego; N R Foster; T C Smyrk; M Le; M J O'Connell; D J Sargent; H Windschitl; F A Sinicrope
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

8.  The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.

Authors:  Seung Tae Kim; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Jin Yong Kim; Young Ho Kim; Dong Kyung Chang; Poong-Lyul Rhee; Dae Shick Kim; Haeran Yun; Yong Beom Cho; Hee Cheol Kim; Seong Hyeon Yun; Ho-Kyung Chun; Woo Yong Lee; Young Suk Park
Journal:  Med Oncol       Date:  2009-12-01       Impact factor: 3.064

9.  Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma.

Authors:  Frank A Sinicrope; Rafaela L Rego; Stephen M Ansell; Keith L Knutson; Nathan R Foster; Daniel J Sargent
Journal:  Gastroenterology       Date:  2009-07-03       Impact factor: 22.682

10.  Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

Authors:  Ioannis Kostopoulos; Vasilios Karavasilis; Maria Karina; Mattheos Bobos; Nikolaos Xiros; George Pentheroudakis; Georgia Kafiri; Pavlos Papakostas; Eleni Vrettou; George Fountzilas
Journal:  BMC Cancer       Date:  2009-09-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.